Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
98 Leser
Artikel bewerten:
(0)

SAVSU Technologies Receives World Health Organization Approval for New Long-Range Vaccine Carrier

SANTA FE, N.M., May 5, 2014 /PRNewswire/ --SAVSU Technologies, an innovative designer and manufacturer of high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced the PQS Certification by the World Health Organization for its PHD' container series.

The PHD' high performance, reusable, long range vaccine carrier is designed for real world applications.

The reusable PHD line is designed for the shipment of biological materials, which must be maintained at 2-8 degrees Celsiusand or controlled room temperature (CRT). The PHD line is designed for small volume shipments from a single dose to 3 liters. Utilizing patent pending antifreeze technology, the PHD reduces the risk of freezing 2-8 degreesCelsiusshipments while the nanoporous insulation allows for extended shipping periods, giving greater product safety assurance in remote or extremely hot areas.

Bruce McCormick, President of SAVSU Technologies and developer of the PHD container commented on the certification saying, "SAVSU is very pleased to see the PHD container approved by the World Health Organization's Performance, Quality and Safety process (PQS). This certification will allow our product to be accessed by organizations world wide that depend on these qualifications to safely transport vaccines to those in need."

McCormick continued by explaining, "The PHD is a long-range vaccine carrier designed for real world applications. It's rugged, reusable, simple to use and extremely high performance design allows for the practical expansion of immunization programs while also helping reduce the overall cost of delivery."

The PHD is only one of the innovative products SAVSU has developed. In April 2014 at the 20th Annual Meeting of the International Society for Cellular Therapy in Paris, France, SAVSU launched the EVO' controlled temperature container as part of an exclusive joint marketing venture with BioLife Solutions, the leading developer and supplier of biopreservation tools to the regenerative medicine, biobanking, and pharmaceutical industries. EVO is the world's first smart shipper designed to continuously monitor a broad range of critical conditions of the payload and the location of the shipment. This data is uploaded in real time to a cloud-based web portal and a mobile application currently in development.

The EVO will be available exclusively through the biologistexSM service, from BioLife Solutions. McCormick commented "We are excited to work with BioLife Solutions as they are a world leader in the field of biopreservation and their expertise, combined with our technology can significantly help biotech companies move faster towards commercialization of their life saving products."

The EVO'  shipper is designed to continuously monitor a broad range of critical conditions of the payload and the location of the shipment in real time.

Photo - http://photos.prnewswire.com/prnh/20140505/84190

Photo - http://photos.prnewswire.com/prnh/20140505/84343

SOURCE SAVSU Technologies

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.